SHANGHAI, 26 de mayo de 2023 /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (en adelante BioRay) anunció que la solicitud de Nuevo Fármaco en Investigación (IND) para el ensayo clínico de su BRY812 patentado, un nuevo conjugado de fármaco anticuerpo (ADC) dirigido al LIV-1 humano para el…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.